These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33021006)

  • 1. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
    Lacouture ME; Sibaud V; Anadkat MJ; Kaffenberger B; Leventhal J; Guindon K; Abou-Alfa G
    Oncologist; 2021 Feb; 26(2):e316-e326. PubMed ID: 33021006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
    Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
    Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
    Meric-Bernstam F; Hollebecque A; Furuse J; Oh DY; Bridgewater JA; Shimura M; Anderson B; Hangai N; Wacheck V; Goyal L
    Clin Cancer Res; 2024 Apr; 30(8):1466-1477. PubMed ID: 38329716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
    Javle M; King G; Spencer K; Borad MJ
    Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.
    Kommalapati A; Tella SH; Borad M; Javle M; Mahipal A
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
    Botrus G; Raman P; Oliver T; Bekaii-Saab T
    Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Futibatinib for
    Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
    N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of FGFR inhibitor-associated toxicities.
    Mahipal A; Tella SH; Kommalapati A; Yu J; Kim R
    Crit Rev Oncol Hematol; 2020 Nov; 155():103091. PubMed ID: 32961472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
    Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
    Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
    Vogel A; Sahai V; Hollebecque A; Vaccaro GM; Melisi D; Al Rajabi RM; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Lihou CF; Zhen H; Veronese ML; Abou-Alfa GK
    ESMO Open; 2024 Jun; 9(6):103488. PubMed ID: 38838500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
    Merz V; Zecchetto C; Melisi D
    Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
    Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
    Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemigatinib-induced nail changes - A case report.
    Trudeau NA; Lawton JM; Patel ND
    J Oncol Pharm Pract; 2021 Oct; 27(7):1795-1798. PubMed ID: 33736556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.